New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice
about
Diffuse large B-cell lymphoma: current strategies and future directionsR-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCLPredicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision MedicineTargeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignanciesThe derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma.From drug discovery to biomarker-driven clinical trials in lymphomaLymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes.A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma.Low T3 syndrome is a strong prognostic predictor in diffuse large B cell lymphoma.Higher incidence of the SNP Met 788 Ile in the coding region of A20 in diffuse large B cell lymphomas.An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma.MicroRNAs as Biomarkers of B-cell LymphomaPrognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose-response meta-analysisAnemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study
P2860
Q28269136-B9D8B1E8-5110-48EE-A88A-FE56225EF1BDQ33934326-786B373E-A402-446D-9739-2C754EC5EC35Q34100855-2B6A4B9E-671E-4ABE-A596-27038D9E4BD2Q35402899-4843226D-2536-49BF-BD9A-5595863073A9Q36152713-8E81A016-753F-42CB-8648-D7720338F74DQ36334833-71C05367-D691-46A8-A42C-B3F33925DA45Q37507473-AD7EE073-8ED7-4BC1-8D1C-9233E61422C2Q37551148-FF024A2B-E550-43E7-8119-2472019054E6Q37706368-022F4032-B586-441D-947E-5F72EED82439Q39077324-CF8C9618-CD43-4A14-A6F0-213DFDE4735AQ40355952-194F5B54-ED91-4631-984A-26F5584327CDQ40373570-45615537-85B1-4647-AE99-C687A54559C7Q47151590-4E25DDDC-3A7B-418F-B423-C5C66C150EC2Q47160551-B38F986E-3D18-4342-956A-9883D66E8D09Q57814100-BF57CD5D-416A-44B2-9D36-9D71333D772DQ58724543-E5CE5292-802F-43BD-989C-313DCEF9459DQ58800059-C72F32DA-A681-49D7-B929-BEEBAADF3662
P2860
New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
New strategies in diffuse larg ...... nalyses into clinical practice
@en
New strategies in diffuse larg ...... alyses into clinical practice.
@nl
type
label
New strategies in diffuse larg ...... nalyses into clinical practice
@en
New strategies in diffuse larg ...... alyses into clinical practice.
@nl
prefLabel
New strategies in diffuse larg ...... nalyses into clinical practice
@en
New strategies in diffuse larg ...... alyses into clinical practice.
@nl
P2860
P1476
New strategies in diffuse larg ...... nalyses into clinical practice
@en
P2093
Jonathan W Friedberg
P2860
P304
P356
10.1158/1078-0432.CCR-11-1073
P407
P577
2011-08-15T00:00:00Z